MRC Technology, Daiichi Sankyo form Drug Discovery Collaboration
News May 14, 2014
MRC Technology announced it has established a drug discovery collaboration with global pharmaceutical company, Daiichi Sankyo. The agreement will focus on the identification and selection of novel drug targets with the potential to become potent and selective therapeutics including oncology, cardiovascular and metabolic diseases.
Under the terms of the agreement, MRC Technology will provide Daiichi Sankyo with details of potential drug targets sourced from academia. Daiichi Sankyo will have the opportunity to work with MRC Technology, who is responsible for screening followed by hit validation and future optimization of selected targets, as part of a collaborative project team. The project provides an ideal opportunity to combine the traditional strengths in drug discovery and development of Daiichi Sankyo with the rich knowledge of targets and disease biology available in academia provided by MRC Technology’s Centre for Therapeutics Discovery.
Justin Bryans, MRC Technology’s Director of Drug Discovery said, “Our aim is to translate early stage academic research into new therapeutic opportunities. Collaborating with Daiichi Sankyo early in this process means we can tap into their wealth of drug discovery experience with the view to generating novel chemical entities faster.”
The collaboration agreement was facilitated by MRC Technology’s agent in Japan, Summit Pharmaceuticals International (SPI).
Target information and financial terms of the agreement have not been disclosed.
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
New Speakers from Roche and Imperial College London Announced for SMi’s ADMET EventNews
SMi Group Reports: With less than 4 weeks left until the 13th annual ADMET Conference commences in London, SMi announces two new speakers joining the event.READ MORE